STAT+ podcast explores new obesity drugs, record IPO and FDA peptide access
On June 11, 2026, STAT’s biotech podcast "The Readout Loud" released an episode that dives into the expanding field of obesity therapeutics.
The hosts review several experimental obesity drugs that are in development, weighing their mechanisms and the challenges they face in a crowded pipeline.
They also note a recent initial public offering that set a new fundraising record for a biotech company, highlighting the market's appetite for weight-loss solutions.
In addition, the discussion touches on the FDA's possible move to broaden access to experimental peptide treatments, which could reshape how these agents are studied and prescribed.
The episode aims to give listeners insight into the commercial and regulatory trends shaping the obesity drug landscape.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: An obesity drug deep-dive, and peptides move mainstream”
read at STAT ↗
comments(0)
5-min edit window · permanent after that